Analysts have lowered their price target for DarioHealth from $19.75 to $18.25. They cited continued revenue weakness, while also anticipating potential recovery driven by a strong pipeline.
Analyst Commentary
Analysts have weighed both encouraging prospects and ongoing challenges in their updated outlook for DarioHealth, reflecting the company’s current market dynamics and future potential.
Bullish Takeaways
- Bullish analysts point to a strong pipeline, which could support a meaningful recovery in revenue growth by 2026.
- Recent upward revisions of price targets suggest improving confidence in the company’s longer-term prospects.
- Analysts see potential valuation upside if DarioHealth can effectively leverage its product updates and execute on new commercial opportunities.
Bearish Takeaways
- Revenue weakness remains a concern as recent quarterly results have not yet demonstrated a clear turnaround.
- Some analysts express caution about the pace of execution and whether pipeline opportunities will materialize quickly enough to drive near-term growth.
- The Hold rating is largely maintained, which highlights ongoing uncertainty in the company's ability to deliver sustained financial improvement.
What's in the News
- DarioHealth announced that its Board is leading a comprehensive strategic review to maximize shareholder value. The company is considering options such as a sale, merger, or continuing with its current standalone strategy (Key Developments).
- The company closed a $17.5 million private placement from 10 investors, strengthening its financial position (Key Developments).
- DarioHealth secured six new employer clients with its value-based pricing model, offering integrated digital health solutions for chronic conditions (Key Developments).
- The company issued updated earnings guidance projecting strong revenue acceleration for 2026 (Key Developments).
- DarioHealth launched five new contracts with self-insured employers, rolling out its full cardiometabolic suite to address multiple chronic conditions (Key Developments).
Valuation Changes
- Consensus Analyst Price Target has fallen from $19.75 to $18.25.
- Discount Rate has risen slightly from 9.19% to 9.21%.
- Revenue Growth estimate remains essentially unchanged at approximately 11.4%.
- Net Profit Margin forecast is stable at roughly 7.1%.
- Future P/E multiple has fallen from 84.6x to 78.3x.
Have other thoughts on DarioHealth?
Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.
Create NarrativeDisclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.